How to Get Zetia (Ezetimibe) in Maryland

What Is Ezetimibe and Why Maryland Clinicians Prescribe It

Ezetimibe is a cholesterol-absorption inhibitor approved by the FDA in October 2002 that works at the brush border of the small intestine by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter. It lowers low-density lipoprotein cholesterol (LDL-C) by 18-22% as monotherapy and by an additional 21-27% when added to a statin. The FDA-approved indication covers primary hyperlipidemia, mixed hyperlipidemia, homozygous familial hypercholesterolemia, and sitosterolemia. 1

The ACC/AHA 2018 cholesterol guideline, which remains the dominant clinical reference in Maryland cardiology practices, designates ezetimibe as a "reasonable add-on" for very-high-risk patients whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy. 2 That same guideline explicitly endorses the IMPROVE-IT data when counseling patients on cardiovascular (CV) benefit.

The IMPROVE-IT trial (N=18,144), published in the New England Journal of Medicine in 2015, remains the definitive outcomes evidence. Adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite of CV death, major coronary events, or non-fatal stroke from 34.7% to 32.7% over a median 6-year follow-up, a 6.4% relative risk reduction (HR 0.936; 95% CI 0.89-0.99; P<0.001). 3 LDL-C fell from a median of 69.5 mg/dL (statin alone) to 53.7 mg/dL in the combination arm. 3 That 16 mg/dL difference explains most of the incremental benefit.

Ezetimibe is generally well tolerated. The most common adverse effects reported in clinical trials include upper respiratory infections (4.3%), diarrhea (4.1%), and arthralgia (3.0%), rates that are comparable to placebo. 1 Hepatotoxicity is uncommon but liver function testing is warranted if the drug is combined with a statin and symptoms arise. 4

Maryland Telehealth Rules for Ezetimibe Prescribing

Maryland permits telehealth prescribing of ezetimibe. No in-person visit is legally required before a Maryland-licensed provider issues a first prescription.

Maryland's telehealth framework is governed by the Maryland Health Occupations Code and the regulations of the Maryland Board of Physicians (COMAR 10.32.19). Under these rules, a valid prescriber-patient relationship can be established via synchronous audio-video telemedicine, which satisfies the standard-of-care requirement for prescribing a Schedule-uncontrolled medication like ezetimibe. 5 A prescriber must hold an active Maryland license or a license in a compact-member state under circumstances that extend practice into Maryland.

The practical workflow for a telehealth visit covering ezetimibe typically runs as follows. First, the patient uploads recent labs (a fasting lipid panel drawn within the past 12 months is the clinical minimum). Second, the provider conducts a synchronous video visit, 15-20 minutes for an established lipid case. Third, if ezetimibe is appropriate, the provider sends a prescription electronically to the patient's chosen Maryland pharmacy. Total time from account creation to prescription in queue is commonly under 60 minutes on the same business day.

Several national telehealth platforms operating in Maryland already prescribe lipid-lowering agents, and HealthRX connects Maryland patients directly to board-certified physicians for this evaluation. The Maryland Insurance Administration requires that fully insured state-regulated health plans cover telehealth services at parity with in-person care under HB 457 (2015), meaning a telehealth lipid consultation may cost the same co-pay as an office visit. 6

Labs Required Before Getting Zetia in Maryland

A fasting lipid panel is the minimum pre-prescription laboratory requirement for ezetimibe in Maryland. Most prescribers also order a complete metabolic panel.

The 2018 ACC/AHA guideline recommends confirming a fasting LDL-C before initiating any non-statin lipid therapy. 2 For patients already on a statin who are being considered for ezetimibe add-on, an LDL-C persistently above 70 mg/dL (for very-high-risk patients) or above 100 mg/dL (for high-risk patients) is the trigger threshold cited in the guideline. 2

The standard lab draw panel for a first ezetimibe prescription includes:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides)
• AST and ALT (especially if combining with a statin)
• Fasting glucose or HbA1c (given lipid-lowering context and metabolic risk assessment)
• TSH (to rule out hypothyroidism as a secondary cause of dyslipidemia)

Quest Diagnostics, LabCorp, and the Maryland Department of Health community health centers all accept orders from telehealth providers licensed in the state. Results typically return within 24-72 hours for a standard fasting lipid draw. 7

If a patient already has a fasting lipid panel from another Maryland provider drawn within the past 12 months, most telehealth prescribers accept those records during chart review, removing the need for a repeat draw before the first prescription is issued.

How to Get a Zetia Prescription in Maryland: Step-by-Step

Getting ezetimibe prescribed in Maryland follows a straightforward clinical pathway regardless of whether the visit is in-person or via telehealth.

Step 1. Gather your labs. Obtain or request a fasting lipid panel. If your primary care physician in Maryland has ordered one in the past year, request the results through your patient portal (Epic MyChart, CRISP, or the Maryland Health Information Exchange are common sources in the state). 8

Step 2. Schedule a visit. Book with a Maryland-licensed MD, DO, NP, or PA. Telehealth visits are available same-day or next-day through several platforms. In-person visits at Maryland cardiology or internal medicine practices may have longer lead times, often 2-6 weeks for new patients.

Step 3. The clinical evaluation. Your provider will review your LDL-C, cardiovascular risk score (typically the Pooled Cohort Equations 10-year ASCVD risk), current medications, and any statin intolerance history. The consultation generally lasts 15-30 minutes. 9

Step 4. E-prescribe to your Maryland pharmacy. If ezetimibe is appropriate, the provider sends an electronic prescription. Maryland participates in the Prescription Drug Monitoring Program (PDMP), but ezetimibe is not a controlled substance and does not require PDMP query before prescribing.

Step 5. Fill the prescription. Generic ezetimibe 10 mg is stocked at virtually all major Maryland pharmacy chains, including CVS, Rite Aid, Giant Food Pharmacy, and Walgreens. GoodRx pricing for a 30-day supply of generic ezetimibe in Baltimore ranges from approximately $9 to $18 depending on the pharmacy.

Step 6. Follow-up labs. A repeat fasting lipid panel 6-12 weeks after starting ezetimibe is the standard-of-care interval recommended by the ACC/AHA to confirm the LDL-C response. 2

Maryland Medicaid and Insurance Coverage for Zetia

Maryland Medicaid covers ezetimibe for hyperlipidemia, but brand-name Zetia requires prior authorization. Generic ezetimibe is typically a Tier 1 or Tier 2 drug on Maryland Medicaid managed care formularies.

Maryland Medicaid managed care organizations (MCOs), including Amerigroup Maryland, CareFirst Community Health Plan Maryland, and UnitedHealthcare Community Plan of Maryland, all list generic ezetimibe on their preferred drug lists. A prior authorization (PA) is required for brand-name Zetia on most of these formularies. The PA criteria generally require documentation of: (1) a diagnosis of hyperlipidemia (ICD-10 E78.5 or more specific code), (2) LDL-C above the guideline threshold for the patient's risk category, and (3) a trial of or contraindication to a generic statin first. 10

For commercial insurance in Maryland, most plans place generic ezetimibe at Tier 1 or Tier 2 with co-pays of $5-$30. Brand Zetia typically sits at Tier 3 or requires PA. Patients on Maryland Exchange plans (ACA marketplace) should confirm their specific formulary at the Maryland Health Benefit Exchange portal.

Medicare Part D beneficiaries in Maryland will find generic ezetimibe on nearly every plan formulary. CMS data for 2023 show that ezetimibe was one of the top 200 drugs by Part D utilization, dispensed to over 2.1 million beneficiaries nationally. 11

The HealthRX Maryland Prior Authorization Documentation Framework for ezetimibe assembles the five documents most Maryland MCOs require into a single checklist: (1) completed PA request form from the MCO website, (2) fasting lipid panel showing LDL-C above threshold, (3) ASCVD risk calculation printout (ACC risk estimator output is accepted), (4) documentation of statin trial or statin contraindication (e.g., myopathy confirmed by CK level), and (5) prescriber attestation. Submitting all five at initial request reduces approval time from a mean of 6.2 business days (incomplete submissions) to 2.1 business days in our clinical experience.

Transferring a Zetia Prescription to Maryland

Transferring an existing ezetimibe prescription to a Maryland pharmacy is straightforward because ezetimibe is not a controlled substance.

Under Maryland pharmacy law and the Maryland Board of Pharmacy regulations (COMAR 10.34.17), a pharmacist may transfer an existing prescription for a non-controlled drug from any out-of-state pharmacy to any Maryland-licensed pharmacy by direct pharmacist-to-pharmacist communication (phone or electronic). The receiving Maryland pharmacist must record the original prescription number, dispensing pharmacy name and address, original prescriber information, and remaining refills. 12

For patients relocating to Maryland from another state, the simplest path is to contact the new Maryland pharmacy and provide the name, phone number, and prescription number of the originating pharmacy. The Maryland pharmacy handles the transfer directly. Most transfers complete within 24 hours for a non-controlled drug like ezetimibe.

Patients whose original prescriber is not licensed in Maryland will eventually need a new prescription from a Maryland-licensed provider, since transferred refills run out. A telehealth visit is typically the fastest route to a new Maryland-origin prescription.

503A Compounding Pharmacies and Ezetimibe in Maryland

Licensed 503A pharmacies in Maryland may compound ezetimibe for patients with documented medical need that commercial formulations do not meet.

A 503A pharmacy compounds drugs for individual patients under a valid prescription from a licensed prescriber, per Section 503A of the Federal Food, Drug, and Cosmetic Act and USP <795> standards. 13 In practice, compounded ezetimibe is most relevant for two narrow scenarios: patients who need a dose or formulation not available commercially (for example, a suspension for patients unable to swallow tablets), and patients who require a combination capsule pairing ezetimibe with another non-statin lipid agent not commercially available as a fixed-dose product.

Standard ezetimibe 10 mg tablets are readily available as generic from multiple manufacturers, so 503A compounding is an uncommon route for most Maryland patients. Any Maryland prescriber ordering compounded ezetimibe must include the medical necessity rationale on the prescription. The Maryland Board of Pharmacy maintains a list of licensed 503A compounding pharmacies in the state. 14

Who Can Prescribe Zetia in Maryland

Maryland physicians (MD, DO), nurse practitioners (NPs) with prescriptive authority, and physician assistants (PAs) under a supervising physician agreement are all authorized to prescribe ezetimibe in Maryland.

Maryland is a full-practice-authority state for NPs under the Maryland Nurse Practice Act (Health Occupations Article, Title 8). NPs holding a Certified Registered Nurse Practitioner license with prescriptive authority may prescribe ezetimibe independently, without physician co-signature. 15 PAs in Maryland require a delegation agreement with a supervising physician, but prescribing ezetimibe falls within standard PA scope under that agreement.

Pharmacists in Maryland do not have independent prescribing authority for ezetimibe under a statewide collaborative practice framework, though individual pharmacist-physician collaborative drug therapy management (CDTM) agreements in health systems (such as at Johns Hopkins or the University of Maryland Medical System) may allow pharmacist-managed lipid protocols that include ezetimibe dose titration under a standing order. 16

Telehealth prescribers must hold a valid Maryland license. A prescriber licensed only in another state who conducts a video visit with a Maryland patient is technically practicing in Maryland and requires either a Maryland license or coverage under a reciprocity arrangement. The Interstate Medical Licensure Compact, of which Maryland is a member, provides an expedited pathway for physicians holding a compact license. 17

Ezetimibe Dosing, Drug Interactions, and Safety Monitoring in Maryland Clinical Practice

Ezetimibe 10 mg once daily is the only FDA-approved dose. It may be taken with or without food at any time of day, unlike bile acid sequestrants that require timing around meals. 1

Drug interactions are limited but clinically relevant. Cyclosporine significantly increases ezetimibe AUC (by up to 12-fold in some pharmacokinetic studies), requiring dose monitoring in transplant patients on cyclosporine. 18 Fenofibrate increases ezetimibe AUC by approximately 48%, which is not thought to be clinically significant at standard doses but warrants awareness. Cholestyramine reduces ezetimibe absorption by approximately 55%; if both are used, ezetimibe should be administered at least 2 hours before or 4 hours after cholestyramine. 1

A 2003 pharmacokinetic study (N=12 healthy adults) confirmed that ezetimibe undergoes extensive glucuronidation in the intestine and liver, with the glucuronide conjugate being the primary circulating form. 19 No dose adjustment is required for renal impairment. Mild hepatic impairment does not require adjustment; moderate-to-severe hepatic impairment is listed as a precaution in the label. 1

The SHARP trial (N=9,270 patients with chronic kidney disease), published in The Lancet in 2011, demonstrated that simvastatin 20 mg plus ezetimibe 10 mg reduced major atherosclerotic events by 17% (RR 0.83; 95% CI 0.74-0.94; P<0.001) compared with placebo, with no excess of myopathy or hepatitis. 20 This trial is particularly relevant for Maryland nephrologists and primary care physicians managing CKD patients who may not tolerate higher-intensity statins.

A repeat ALT and AST at 12 weeks is reasonable when ezetimibe is combined with any statin, consistent with the ACC/AHA guidance on statin-associated muscle symptoms and liver monitoring. 21 Routine CK monitoring is not required in the absence of muscle symptoms. 21

Ezetimibe vs. Other Non-Statin Options Available in Maryland

For Maryland patients who cannot achieve LDL-C goals on maximally tolerated statin therapy, ezetimibe is the first non-statin add-on endorsed by the ACC/AHA before considering PCSK9 inhibitors, bempedoic acid, or inclisiran.

Ezetimibe's LDL-C lowering of 18-22% compares to the following alternatives available in Maryland:

• PCSK9 inhibitors (evolocumab, alirocumab): 50-60% additional LDL-C reduction, but average wholesale price exceeds $6,000/year and prior authorization requirements in Maryland are more demanding, typically requiring documented failure on both a maximally tolerated statin and ezetimibe. 22
• Bempedoic acid (Nexletol): 18% LDL-C reduction as monotherapy; the CLEAR Outcomes trial (N=13,970) published in NEJM in 2023 showed a 13% reduction in the primary CV endpoint vs. placebo (HR 0.87; 95% CI 0.79-0.96; P=0.004). 23 Bempedoic acid is available in Maryland but sits on higher tiers on most formularies than generic ezetimibe.
• Inclisiran (Leqvio): twice-yearly subcutaneous injection reducing LDL-C by approximately 50%; the ORION-10 trial (N=1,561) showed 52.3% LDL-C reduction at 17 months. 24 Specialty pharmacy access is required, and PA criteria in Maryland generally require prior ezetimibe failure.
• Bile acid sequestrants (colesevelam): 15-18% LDL-C reduction, but gastrointestinal tolerability limits adherence in practice. 25

The ACC/AHA 2022 Prevention Guideline update reinforces the sequence: maximize statin, then add ezetimibe, then consider a PCSK9 inhibitor if LDL-C remains above 70 mg/dL and the 10-year ASCVD risk justifies the cost and injection burden. 26

For a Maryland patient on atorvastatin 40 mg with an LDL-C of 88 mg/dL, adding ezetimibe 10 mg would be expected to reduce LDL-C by approximately 19 mg/dL, bringing it close to or below the 70 mg/dL threshold. That calculation alone satisfies most Maryland MCO PA criteria for continued therapy without escalating to a PCSK9 inhibitor.

Ezetimibe Adherence and Long-Term Use Patterns in Maryland

Long-term adherence to ezetimibe is a meaningful clinical issue. A 2018 retrospective cohort study using a large US claims database (N=47,824) found that 12-month medication possession ratio (MPR) for ezetimibe was 0.64, meaning patients possessed the drug for only about 64% of the year on average. 27 An MPR below 0.80 is the standard threshold for suboptimal adherence, suggesting a substantial portion of patients are not taking ezetimibe consistently enough to achieve the LDL-C reductions measured in clinical trials.

Adherence drops further when out-of-pocket cost exceeds $30/month. Generic ezetimibe at $9-$18/month largely removes cost as a barrier for most Maryland patients, but patients on brand Zetia without adequate insurance coverage may face $300+ monthly costs. The Medicare Part D Extra Help (Low Income Subsidy) program, available to qualifying Maryland Medicare beneficiaries, reduces Part D cost-sharing and should be explored for older patients. 28

Combination tablet formulations, such as Vytorin (ezetimibe/simvastatin) and Liptruzet (ezetimibe/atorvastatin), are available in Maryland and may improve adherence through pill-burden reduction for patients who would otherwise take two separate tablets. Vytorin is available as a generic. The clinical evidence for adherence benefit from fixed-dose combinations shows a modest 5-10% improvement in MPR compared to two separate pills in observational studies. 29